Research is investigating its effects on non-alcoholic steatohepatitis (NASH), cardiovascular outcomes, and its role in reducing the risk of developing type 2 diabetes in individuals with prediabetes
Clinical trials have shown that individuals using Wegovy experienced an average weight loss of around 15% of their initial body weight over the course of the trial
GLP-1 injectable medications, such as semaglutide (Wegovy) and tirzepatide (Zepbound), are showing powerful results in weight management
ACC 57) at passage 425 were cultured in Dulbeccos Modified Eagle Medium (DMEM) (Gibco, Ref: 41966029, Thermofisher Scientific,Waltham, Massachusetts, United States) supplemented with 10% foetal bovine serum (FBS) (Gibco, Ref: 10270106, Thermo Fisher Scientific, Waltham, Massachusetts, United States) in humidified air at 37 C and 5% CO 2
Subsequent testing following infusion of MT-II or normal saline was done on the indicated days post-infusion